We are live on ! Find out more
ENGNW icon

enGene Therapeutics Warrants
ENGNW

11 hedge funds and large institutions have $12.9M invested in enGene Therapeutics Warrants in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

2% more ownership

Funds ownership: 46.54% → 48.54% (+2%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

7% less capital invested

Capital invested by funds: $13.9M → $12.9M (-$990K)

21% less funds holding

Funds holding: 14 → 11 (-3)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
11
Holders Change
-3
Holders Change %
-21.43%
% of All Funds
0.14%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
2
Increased
2
Reduced
1
Closed
5
Calls
$175K
Puts
–
Net Calls
+$175K
Net Calls Change
-$29K

Top Buyers

Rank Fund Capital Flow
1
BOCH
Blue Owl Capital Holdings
New York
+$1.41M
2
LP
LMR Partners
United Kingdom
+$715K
3
AC
Aristeia Capital
Connecticut
+$487K
4
ICM
Ionic Capital Management
New York
+$49.6K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$844K
2
CM
Caption Management
Oklahoma
-$420K
3
Calamos Advisors
Calamos Advisors
Illinois
-$418K
4
SCM
Saba Capital Management
New York
-$288K
5
WAM
Wolverine Asset Management
Illinois
-$48K
Name Holding Trade Value Shares
Change 		Change in
Stake
FIS
1
FCPM III Services
Netherlands
$7.28M – – –
BI
2
BVF Inc
California
$2.49M – – –
BOCH
3
Blue Owl Capital Holdings
New York
$1.29M +$1.41M +475,077 +1,316%
LP
4
LMR Partners
United Kingdom
$811K +$715K +241,160 +303%
AC
5
Aristeia Capital
Connecticut
$445K +$487K +164,511 New
D.E. Shaw & Co
6
D.E. Shaw & Co
New York
$275K – – –
TCM
7
Tenor Capital Management
New York
$140K – – –
SCM
8
Saba Capital Management
New York
$101K -$288K -97,301 -71%
CL
9
CSS LLC
Illinois
$42.7K – – –
ICM
10
Ionic Capital Management
New York
$42.4K +$49.6K +16,753 New
CS
11
Clear Street
New York
$759 – – –
VC
12
Vivo Capital
California
– -$844K -285,046 Closed
Calamos Advisors
13
Calamos Advisors
Illinois
– -$418K -148,290 Closed
CM
14
Caption Management
Oklahoma
– -$420K -141,904 Closed
WAM
15
Wolverine Asset Management
Illinois
– -$48K -16,223 Closed
Bank of America
16
Bank of America
North Carolina
– -$798 -300 Closed

ENGNW Hedge Fund Activity: Q1 2026 in Review

11 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics Warrants (ENGNW) for Q1 2026, worth a combined $12.9M — down 7.1% from $13.9M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ENGNW and 2 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was Blue Owl Capital Holdings, adding an estimated $1.41M. The largest seller was Vivo Capital, exiting entirely with an estimated $844K sold.

  • 11 institutional investors held enGene Therapeutics Warrants (ENGNW) as of Q1 2026, down from 14 in Q4 2025.
  • Funds reported $12.9M of enGene Therapeutics Warrants stock for Q1 2026, down 7.1% quarter-over-quarter.
  • 2 funds opened new enGene Therapeutics Warrants positions in Q1 2026 and 5 closed out, a net change of -3 holders.
  • The largest enGene Therapeutics Warrants buyer in Q1 2026 was Blue Owl Capital Holdings, an estimated $1.41M added.
  • The largest enGene Therapeutics Warrants seller in Q1 2026 was Vivo Capital, an estimated $844K sold.

Based on aggregated 13F filings for Q1 2026.